Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies

 Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies

Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies

Shots:

  • Seed Therapeutics to receive $10M upfront, $10M equity investment, ~$780M as pre/clinical development, regulatory & commercial milestones along with royalties on net sales of products that emerges from the collaboration
  • Seed utilizes molecular glue protein degradation technology to develop potential new therapies
  • The agreement allows Seed to advance its platform to deliver new molecules targeting proteins that cause human diseases

Click here ­to­ read full press release/ article | Ref: Globe Newswire | Image: Medium

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post